Literature DB >> 2353121

[Thyroid clinical dysfunction in patients chronically treated with amiodarone].

R V García1, M Gómez Sobreira, J Batista, M Moreiras, J Lázaro Enguis, D Alvarez Gándara.   

Abstract

This is a prospective study of 132 patients, without previous thyroid dysfunction, chronically treated with amiodarone for cardiac arrhythmias, to determine the incidence of thyroid dysfunction. Age was 62 +/- 11 years (mean +/- SD); 54 were female and 78 male. The arrhythmia was supraventricular in 66%, ventricular in 26.5%, and both in 7.5%. Amiodarone dose was 2,390 +/- 65 mg/week, and follow-up 20 +/- 9 months (minimum 9 months). Thyroid status was evaluated at the onset and at regular intervals during follow-up by means of clinical indexes defined by Crooks et al and Billewicz et al. During follow-up 4 patients developed diagnostic indexes (two hyperthyroid and two hypothyroid) and seven more developed suggestive symptoms without reaching a diagnostic index. Biochemical serum determinations of thyroid function proved dysfunction in the four with diagnostic indexes, and were normal in the other seven. The prevalence of new thyroid dysfunction in patients chronically treated with amiodarone in our population is 3%, with equal incidence of hyper and hypofunction. This is the expected incidence for an area with adequate dietary iodine intake. The use of clinical indexes of thyroid dysfunction appear as a useful and economical means of following thyroid function in these patients, saving a large number of biochemical tests.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2353121

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  2 in total

1.  Increased incidence of thyrotoxicosis after iodine supplementation in an iodine sufficient area.

Authors:  J C Galofré; L Fernández-Calvet; M Ríos; R V García-Mayor
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

2.  Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

Authors:  R V García-Mayor; C Páramo; R Luna Cano; L F Pérez Mendez; J C Galofré; A Andrade
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.